Literature DB >> 19454299

Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats.

Larissa de Oliveira1, Cecília Marly dos S Spiazzi, Thaize Bortolin, Leila Canever, Fabricia Petronilho, Franciele Gonçalves Mina, Felipe Dal-Pizzol, João Quevedo, Alexandra I Zugno.   

Abstract

Schizophrenia is a complex neuropsychiatric disorder in which symptoms can be classified as either positive, such as delusions and hallucinations, or negative, such as blunted affect and social withdrawal. However, the mechanisms underlying this disease are poorly understood. There is evidence that reactive oxygen species (ROS) play an important role in the pathogenesis of many diseases, particularly those which are neurological and psychiatric in nature. Ketamine has been used to induce a schizophrenia-like condition as an animal model in which to study this condition. In the present study we tested the effects of sub-anesthetic doses of ketamine on various parameters of oxidative stress in the brain of rats. Our results indicate that lipid peroxidation and tissue protein oxidation were affected by varying sub-anesthetic doses of ketamine in multiple cerebral structures. Additionally, the activity of the antioxidant enzymes CAT and SOD was measured and was also found to be altered in most of the structures tested. In conclusion, we observe an increase in oxidative damage marked by an increase in lipid peroxidation, oxidative protein damage and a decrease in enzymatic defenses, in an animal model of schizophrenia. Given that oxidative stress could be related to schizophrenia, these findings may explain, at least in part, the mechanisms underlying in this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19454299     DOI: 10.1016/j.pnpbp.2009.05.010

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  24 in total

1.  Energization by multiple substrates and calcium challenge reveal dysfunctions in brain mitochondria in a model related to acute psychosis.

Authors:  Jamila Monteiro; Gabriela Assis-de-Lemos; Eduardo de-Souza-Ferreira; Adriana M Marques; Gilda A Neves; Mariana S Silveira; Antonio Galina
Journal:  J Bioenerg Biomembr       Date:  2019-12-18       Impact factor: 2.945

2.  A behavioral and molecular analysis of ketamine in zebrafish.

Authors:  Sherry M Zakhary; Diana Ayubcha; Farah Ansari; Kiran Kamran; Mehwish Karim; Joerg R Leheste; Judith M Horowitz; German Torres
Journal:  Synapse       Date:  2011-02       Impact factor: 2.562

3.  Ketamine induces immediate and delayed alterations of OCD-like behavior.

Authors:  Summer L Thompson; Amanda C Welch; Julia Iourinets; Stephanie C Dulawa
Journal:  Psychopharmacology (Berl)       Date:  2020-01-11       Impact factor: 4.530

4.  Anesthetic Ketamine-Induced DNA Damage in Different Cell Types In Vivo.

Authors:  Daniela Dimer Leffa; Bruno Nunes Bristot; Adriani Paganini Damiani; Gabriela Daminelli Borges; Francine Daumann; Gabriela Maria Zambon; Gabriela Elibio Fagundes; Vanessa Moraes de Andrade
Journal:  Mol Neurobiol       Date:  2015-10-17       Impact factor: 5.590

5.  The nitric oxide donor sodium nitroprusside attenuates recognition memory deficits and social withdrawal produced by the NMDA receptor antagonist ketamine and induces anxiolytic-like behaviour in rats.

Authors:  Aikaterini Trevlopoulou; Ntilara Touzlatzi; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2015-12-19       Impact factor: 4.530

6.  Protective effect of gallic acid in experimental model of ketamine-induced psychosis: possible behaviour, biochemical, neurochemical and cellular alterations.

Authors:  Monu Yadav; Deepak Kumar Jindal; Mamta Sachdeva Dhingra; Anil Kumar; Milind Parle; Sameer Dhingra
Journal:  Inflammopharmacology       Date:  2017-06-02       Impact factor: 4.473

7.  Zoletil promotes apoptosis in BV-2 microglial cells via induction of oxidative stress and neural inflammation.

Authors:  Gyun Moo Kim; Chan Lee; Tae Chang Jang
Journal:  Toxicol Res (Camb)       Date:  2021-12-29       Impact factor: 3.524

8.  Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.

Authors:  Georgia Georgiadou; Vasilios Grivas; Petros A Tarantilis; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

9.  Rivastigmine reverses cognitive deficit and acetylcholinesterase activity induced by ketamine in an animal model of schizophrenia.

Authors:  Alexandra I Zugno; Ricardo Filipe Julião; Josiane Budni; Ana Maria Volpato; Daiane B Fraga; Felipe D Pacheco; Pedro F Deroza; Renata D Luca; Mariana B de Oliveira; Alexandra S Heylmann; João Quevedo
Journal:  Metab Brain Dis       Date:  2013-06-19       Impact factor: 3.584

10.  A rodent model of schizophrenia reveals increase in creatine kinase activity with associated behavior changes.

Authors:  Leila Canever; Larissa Oliveira; Renata D'Altoé de Luca; Paulo T F Correa; Daiane de B Fraga; Maria Paula Matos; Giselli Scaini; João Quevedo; Emílio L Streck; Alexandra I Zugno
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.